UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER

Dr. Neil Desai discussed the role of ADT and genomic risk stratification for unfavorable intermediate-risk prostate cancer at the 2024 ASTRO annual meeting, emphasizing the use of advanced risk classifiers like Decipher, Prolaris, Oncotype DX GPS, and MMAI to guide treatment decisions, including the duration of ADT and RT intensity.

U.S. shortages of GLP-1 drugs like Ozempic and Mounjaro have led to competition between drugmakers and compounded versions, with telehealth companies like Hims & Hers and Noom offering cheaper alternatives. Pharmaceutical giants Novo Nordisk and Eli Lilly have sued competitors for selling 'copycat' drugs, while federal agencies express concern over adverse events from compounded semaglutide. Compounded drugs are not FDA-approved and come from 503B facilities, with telehealth companies sourcing from FDA-regulated manufacturers. Doctors prefer FDA-approved versions due to safety concerns.

Dana-Farber Cancer Institute launches IGNITE, the first national pediatric hematology-oncology health equity research consortium, aiming to address disparities in cancer outcomes for children from low-income households and marginalized communities by developing and evaluating health equity interventions.

Clarivate Plc unveils Citation Laureates 2024, forecasting Nobel Prize recipients based on extraordinary citation records and societal impact. This year's 22 laureates span six countries and have made significant contributions to fields like clean energy, nanotechnology, and quantum computing.

ImmuneSensor Therapeutics' CEO, Tom Dubensky, will present a corporate update at the UBS 2024 Virtual Biotechnology Private Company Symposium on Sept. 19, 2024, at 10:30 am ET. The presentation will be webcast live and archived on the company's website for 30 days.

ImmuneSensor Therapeutics' CEO, Tom Dubensky, will present a corporate update at the UBS 2024 Virtual Biotechnology Private Company Symposium on Sept. 19, 2024. The presentation will be webcast live and archived on the company's website for 30 days.

Tonix Pharmaceuticals launched an educational campaign at PAINWeek highlighting non-oral migraine treatments for patients with gastroparesis, emphasizing faster relief via nasal sprays and injectables.

TN-201, a gene therapy for cardiomyopathy, is projected to generate $37 mn in annual revenue by 2038 in the US. Tenaya Therapeutics, the developer, uses a risk-adjusted NPV model (rNPV) to assess investment value, considering R&D costs and approval likelihood. The company reported operating and net losses of $131.2 mn and $124.1 mn respectively in FY2023.

C. Michael Gibson discovered high lipoprotein(a) levels, inherited from his grandfather, despite decent cholesterol. Research is ongoing for medications to lower lipoprotein(a) and other approaches to reduce cardiovascular disease risk. Statins are effective but not sufficient, prompting exploration of new treatments targeting various cholesterol types, including HDL and remnant cholesterol. Clinical trials are underway, with mixed results so far, but optimism remains for potential breakthroughs.

Tonix Pharmaceuticals launches educational campaign on non-oral migraine treatments, highlighting faster relief via nasal and injectable options, addressing gastroparesis' impact on oral medication efficacy.